Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Melanoma
"Double-Copy Bicistronic Retroviral Vector Platform for Gene Therapy and Tissue Engineering: Application to Melanoma Vaccine Development."
November 24th, 1997
According to the authors' abstract of an article published in Gene Therapy, "The efficient genetic modification of solid tumors in situ to stimulate therapeutic immune responses against them is currently under active investigation, but is not yet possible using existing gene transfer technologies. Thus, ex vivo/in vivo vaccination strategies have been proposed in which the patient's tumor is surgically excised, single cell suspensions are, the therapeutic genes are introduced and then the gene-modified cells, after being gamma-irradiated, are injected back into the patient. However, even with high-efficiency gene delivery systems, this is a labor-intensive process. Moreover, it is often...
Source: Cancer Weekly (1997-11-24)
|
|
Advertisement |
|
|
